Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis

Clinical Biochemistry

Volumn 40, Issue 5-6, 2007, Pages 336-342

  Matzaraki, Vassiliki ^a   Alexandraki, Krystallenia I ^b,c   Venetsanou, Kyriaki ^a   Piperi, Christina ^c   Myrianthefs, Pavlos ^a   Malamos, Nikolaos ^d   Giannakakis, Theodoros ^b   Karatzas, Stelios ^a   Diamanti Kandarakis, Evanthia ^e   Baltopoulos, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b AGII ANARGIRI CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d Maternity Hospital Elena Venizelou   (Greece)

^e LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Cytokines; Generalized metastasis; Inflammation markers; Interleukin 6; Liver metastasis; Procalcitonin; Solid tumors; Tumor markers

Indexed keywords

INTERLEUKIN 6; PROCALCITONIN;

ADULT; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; EVALUATION; FEMALE; HUMAN; LIVER METASTASIS; MALE; PRIORITY JOURNAL; SOLID TUMOR;

AGED; ANALYSIS OF VARIANCE; CALCITONIN; FEMALE; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33847294154     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.10.027     Document Type: Article

References (59)

1. Takeda A., Stoeltzing O., Ahmad S.A., et al. Role of angiogenesis in the development and growth of liver metastasis. Ann. Surg. Oncol. 9 (2002) 610-616
2. Assicot M., Gendrel D., Carsin H., Raymond J., Guilbaud J., and Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341 (1993) 515-518
3. Le Moullec J.M., Jullienne A., Chenais J., et al. The complete sequence of human preprocalcitonin. FEBS Lett. 167 (1984) 93-97
4. Russwurm S., Wiederhold M., Oberhoffer M., Stonans I., Zipfel P.F., and Reinhart K. Molecular aspects and natural source of procalcitonin. Clin. Chem. Lab. Med. 37 (1999) 789-797
5. Becker K.L., O'Neil W.J., Snider Jr. R.H., et al. Hypercalcitonemia in inhalation burn injury: a response of the pulmonary neuroendocrine cell?. Anat. Rec. 236 (1993) 136-138 (172-3; discussion 138-143)
6. Oberhoffer M., Vogelsang H., Jager L., and Reinhart K. Katacalcin and calcitonin immunoreactivity in different types of leukocytes indicate intracellular procalcitonin content. J. Crit Care 14 (1999) 29-33
7. Kretzschmar M., Kruger A., and Schirrmeister W. Procalcitonin following elective partial liver resection-origin from the liver?. Acta Anaesthesiol. Scand. 45 (2001) 1162-1167
8. Brunkhorst F.M., Wegscheider K., Forycki Z.F., and Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med. 26 Suppl. 2 (2000) S148-S152
9. Schwarz S., Bertram M., Schwab S., Andrassy K., and Hacke W. Serum procalcitonin levels in bacterial and abacterial meningitis. Crit. Care Med. 28 (2000) 1828-1832
10. Gerard Y., Hober D., Assicot M., et al. Procalcitonin as a marker of bacterial sepsis in patients infected with HIV-1. J. Infect. 35 (1997) 41-46
11. Bertsch T., Richter A., Hofheinz H., Bohm C., Hartel M., and Aufenanger J. Procalcitonin. A new marker for acute phase reaction in acute pancreatitis. Langenbecks Arch. Chir. 382 (1997) 367-372
12. de Werra I., Jaccard C., Corradin S.B., et al. Cytokines, nitrite/nitrate, soluble tumour necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit. Care Med. 25 (1997) 607-613
13. Kuse E.R., Langefeld I., Jaeger K., and Kulpmann W.R. Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit. Care Med. 28 (2000) 555-559
14. Silva O.L., Broder L.E., Doppman J.L., et al. Calcitonin as a marker for bronchogenic cancer: a prospective study. Cancer 44 (1979) 680-684
15. Cheval C., Timsit J.F., Garrouste-Orgeas M., Assicot M., De Jonghe B., Misset B., et al. Procalcitonin (PCT) is useful in predicting the bacterial origin of an acute circulatory failure in critically ill patients. Intensive Care Med. 26 Suppl. 2 (2000) S153-S158
16. Becker K.L., Nylen E.S., White J.C., Muller B., and Snider Jr. R.H. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J. Clin Endocrinol. Metab. 89 (2004) 1512-1525
17. Takeda K., Fujii N., Nitta Y., et al. Murine tumour cells metastasizing selectively in the liver: ability to produce hepatocyte-activating cytokines interleukin-1 and/or -6. Jpn. J. Cancer Res. 82 (1991) 1299-1308
18. Opdenakker G., and Van Damme J. Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Cytokine 4 (1992) 251-258
19. Basso D., Plebani M., Fogar P., Panozzo M.P., Meggiato T., De Paoli M., et al. Insulin-like growth factor-I, interleukin-1 alpha and beta in pancreatic cancer: role in tumour invasiveness and associated diabetes. Int. J. Clin Lab. Res. 25 1 (1995) 40-43
20. Scheller J., Ohnesorge N., and Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand. J. Immunol. 63 (2006) 321-329
21. Kutteh W.H., Rainey W.E., and Carr B.R. Regulation of interleukin-6 production in human fetal Kupffer cells. Scand. J. Immunol. 33 (1991) 607-613
22. Liu X.H., Kirschenbaum A., Lu M., et al. Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem. Biophys. Res. Commun. 290 (2002) 249-255
23. Chang C.Y., Li M.C., Liao S.L., Huang Y.L., Shen C.C., and Pan H.C. Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J. Clin. Neurosci. 12 (2005) 930-933
24. Tamm I., Cardinale I., Kikuchi T., and Krueger J.G. E-cadherin distribution in interleukin 6-induced cell-cell separation of ductal breast carcinoma cells. Proc. Natl. Acad Sci. U. S. A. 91 (1994) 4338-4342
25. Costes V., Liautard J., Picot M.C., Robert M., Lequeux N., Brochier J., et al. Expression of the interleukin 6 receptor in primary renal cell carcinoma. J. Clin. Pathol. 50 10 (1997 (Oct.)) 835-840
26. Andrews B., Shariat S.F., Kim J.H., Wheeler T.M., Slawin K.M., and Lerner S.P. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J. Urol. 167 (2002) 1475-1481
27. Garcia-Tunon I., Ricote M., Ruiz A., Fraile B., Paniagua R., and Royuela M. IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology 47 (2005) 82-89
28. Givon T., Slavin S., Haran-Ghera N., Michalevicz R., and Revel M. Antitumour effects of human recombinant interleukin-6 on acute myeloid leukemia in mice and in cell cultures. Blood 79 (1992) 2392-2398
29. Eisenthal A., Kashtan H., Rabau M., Ramakrishna V., Chaitchik S., and Skornick Y. Antitumour effects of recombinant interleukin-6 expressed in eukaryotic cells. Cancer Immunol. Immunother. 36 (1993) 101-107
30. Takizawa H., Ohtoshi T., Ohta K., Yamashita N., Hirohata S., Hirai K., et al. Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumour growth via an autocrine mechanism. Cancer Res. 53 (1993) 4175-4181
31. Jessup J.M., Laguinge L., Lin S., Samara R., Aufman K., Battle P., et al. Carcinoembryonic antigen induction of IL-10 and IL-6 inhibits hepatic ischemic/reperfusion injury to colorectal carcinoma cells. Int. J. Cancer 111 (2004) 332-337
32. Kanno H., Yasunaga Y., Iuchi K., et al. Interleukin-6-mediated growth enhancement of cell lines derived from pyothorax-associated lymphoma. Lab. Invest. 75 (1996) 167-173
33. Moran D.M., Mayes N., Koniaris L.G., Cahill P.A., and McKillop I.H. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma. Liver Int. 25 (2005) 445-457
34. Todo T., Adams E.F., Rafferty B., Fahlbusch R., Dingermann T., and Werner H. Secretion of interleukin-6 by human meningioma cells: possible autocrine inhibitory regulation of neoplastic cell growth. J. Neurosurg. 81 (;1994) 394-401
35. Chen L., Shulman L.M., and Revel M. IL-6 receptors and sensitivity to growth inhibition by IL-6 in clones of human breast carcinoma cells. J. Biol. Regul. Homeost. Agents 5 (1991) 125-136
36. Brozek W., Bises G., Girsch T., Cross H.S., Kaiser H.E., and Peterlik M. Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumour progression. Eur. J. Cancer 41 (2005) 2347-2354
37. Hutchins D., and Steel C.M. Regulation of ICAM-1 (CD54) expression in human breast-cancer cell-lines by interleukin-6 and fibroblast-derived factors. Int. J. Cancer 58 (1994) 80-84
38. de Jong K.P., van Gameren M.M., Bijzet J., et al. Recombinant human interleukin-6 induces hepatocyte growth factor production in cancer patients. Scand. J. Gastroenterol. 36 (2001) 636-640
39. Cohen T., Nahari D., Cerem L.W., Neufeld G., and Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 271 (1996) 736-741
40. Zhang G.J., and Adachi I. Serum interleukin-6 levels correlate to tumour progression and prognosis in metastatic breast carcinoma. Anticancer Res. 19 (1999) 1427-1432
41. Shariat S.F., Kim J.H., Andrews B., et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer 92 (2001) 2985-2992
42. Oka M., Yamamoto K., Takahashi M., et al. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res. 56 (1996) 2776-2780
43. Mouawad R., Benhammouda A., Rixe O., et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumour burden. Clin. Cancer Res. 2 (1996) 1405-1409
44. Berek J.S., Chung C., Kaldi K., Watson J.M., Knox R.M., and Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am. J. Obstet. Gynecol. 164 (1991) 1038-1042 (discussion 1042-1043)
45. Wu C.W., Wang S.R., Chao M.F., et al. Serum interleukin-6 levels reflect disease status of gastric cancer. Am. J. Gastroenterol. 91 (1996) 1417-1422
46. Belluco C., Nitti D., Frantz M., Toppan P., Basso D., Plebani M., et al. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann. Surg. Oncol. 7 (2000) 133-138
47. Ghillani P.P., Motte P., Troalen F., et al. Identification and measurement of calcitonin precursors in serum of patients with malignant diseases. Cancer Res. 49 (1989) 6845-6851
48. Giamarellos-Bourboulis E.J., Mega A., Grecka P., Scarpa N., Koratzanis G., Thomopoulos G., et al. Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient?. Intensive Care Med. 28 (2002) 1351-1356
49. Muller B., Becker K.L., Schachinger H., Zimmerli W., and Ritz R. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit. Care Med. 28 (2000) 977-983
50. Mayer P., Geissler K., Valent P., Ceska M., Bettelheim P., and Liehl E. Recombinant human interleukin 6 is a potent inducer of the acute phase response and elevates the blood platelets in nonhuman primates. Exp. Hematol. 19 (1991) 688-696
51. Garcia de Galdeano L., Boyano D., Smith-Zubiaga I., Alvarez A., Canton I., and Canavate L. Involvement of interleukin-6 in the biology and metastatic activity of B16F10 melanoma cells. Eur. Cytokine Netw. 9 (1998) 187-192
52. Wang L.S., Chow K.C., and Wu C.W. Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate. Br. J. Cancer 80 (1999) 1617-1622
53. Fogar P., Basso D., Pasquali C., Piva M.G., Brigato L., DePaoli M., et al. Portal but not peripheral serum levels of interleukin 6 could interfere with glucose metabolism in patients with pancreatic cancer. Clin. Chim. Acta 277 (1998) 181-189
54. Ueda T., Shimada E., and Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J. Gastroenterol. 29 (1994) 423-429
55. de Jong K.P., van Gameren M.M., and Bijzet J. Recombinant human interleukin-6 induces hepatocyte growth factor production in cancer patients. Scand. J. Gastroenterol. 36 6 (2001 (Jun.)) 636-640
56. Cohen T., Nahari D., Cerem L.W., Neufeld G., and Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 271 (1996) 736-741
57. Schneider M.R., Hoeflich A., Fischer J.R., Wolf E., Sordat B., and Lahm H. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett. 151 (2000) 31-38
58. Andela V.B., Schwarz E.M., Puzas J.E., O'Keefe R.J., and Rosier R.N. Tumour metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. Cancer Res. 60 (2000) 6557-6562
59. Lee S.Y., Lim J.W., and Kim Y.M. Effect of alpha1-acid glycoprotein expressed in cancer cells on malignant characteristics. Mol. Cells 11 (2001) 341-345